A look back on the Biden administration’s most significant actions impacting food and farming during the president’s tenure.

The Biden administration's Food and Drug Administration (FDA) released additional details on a proposed rule that would effectively ban cigarettes currently on the market.

The proposal in the waning days of the Biden administration leaves it up to President-elect Donald Trump to finalize the effort — or scrap it.

President Joe Biden is using the last days of his presidency to pursue some of the long-term goals of the administration, particularly when it comes to issues of drugs, whether legal or criminalized.

A proposed FDA rule would mandate a reduction to minimally addictive or nonaddictive levels, but the incoming Trump administration isn’t expected to follow through on the idea.

The rescinded order directed Medicare and Medicaid to test ways to lower drug costs for enrollees. Those tests hadn’t started, so current drug prices are unaffected.

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Biden leaving 11th-hour health measures for TrumpThe Biden administration in its final days has been

The Biden administration is ending its term ... as well as to the overdose-reversal medication naloxone, which the Food and Drug Administration approved for over-the-counter use in 2023.

WASHINGTON — President Trump began his second term Monday with a sweeping order aimed at reversing dozens of former President Biden’s top priorities, from regulations aimed at lowering health care costs, to coronavirus outreach, Affordable Care Act expansions, and protections against gender-based discrimination.

Federal officials on Wednesday released a far-reaching proposal to make cigarettes far less addictive by capping their nicotine content.

The Trump administration’s first drug pricing action — rescinding a Biden executive order encouraging Medicare to help lower prescription costs — is befuddling drug pricing experts.

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation and patient access to treatments.